Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility

Zimmer,Vincent; Höblinger,Aksana; Mihalache,Florentina; Assmann,Gunter; Acalovschi,Monica; Lammert,Frank

doi:10.3892/ol.2012.680

Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility

Authors:
- Vincent Zimmer
- Aksana Höblinger
- Florentina Mihalache
- Gunter Assmann
- Monica Acalovschi
- Frank Lammert
View Affiliations

Affiliations: Department of Medicine II, Saarland University Hospital, Homburg, Germany, Department of Medicine I, University Hospital Bonn, Bonn, Germany, Department of Medicine III, University Iuliu Hatieganu, Cluj-Napoca, Romania, Department of Medicine I, Saarland University Hospital, Homburg, Germany, Department of Medicine II, Saarland University Hospital, Homburg, Germany
Published online on: April 17, 2012 https://doi.org/10.3892/ol.2012.680
Pages: 101-106

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant cell cycle control and apoptosis deregulation are involved in biliary carcinogenesis. The tumor suppressor gene p53 and its key negative regulator murine double minute 2 (mdm2) cooperate in modulating these basic cell functions and germline p53 alteration promotes cholangiocarcinoma (CCA) formation in animal models. The potential association between common functional genetic variation in p53 (SNP72 G/C) and mdm2 (SNP309 T/G) and susceptibility to bile duct cancer, however, has not been studied. p53/SNP72 G/C (rs1042522) and mdm2/SNP309 T/G (rs2279744) were genotyped in 182 Caucasian CCA patients and 350 controls using TaqMan assays. Allelic and genotypic differences, including exploratory data analyses (according to gender, tumor localization, early onset and genotypic interactions) were compared in contingency tables using the χ2 and Fisher's exact tests. The overall comparison of allele and genotype frequencies yielded no significant association between either SNP and CCA susceptibility. Similarly, gender- and localization-specific analyses did not reveal deviations in allelic or genotypic distributions. In carriers of the low-apoptotic p53 genotype CC, the mdm2 SNP309 T allele conferred borderline significant CCA risk [P=0.049; odds ratio (OR), 4.36; 95% CI, 0.92-20.77]. Power analysis confirmed adequate statistical power to exclude major SNP effects (each >97% for OR 1.7). Collectively, the results we obtained from the largest European CCA cohort do not support the hypothesis of a prominent role of common p53 and mdm2 variation in the genetic susceptibility to bile duct cancer. However, epistatic effects may modulate genetic CCA risk in individual subsets.

View Figures

View References

1	Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314. 2005. View Article : Google Scholar : PubMed/NCBI
2	Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004. View Article : Google Scholar : PubMed/NCBI
3	Cardinale V, Semeraro R, Torrice A, et al: Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol. 2:407–416. 2010. View Article : Google Scholar : PubMed/NCBI
4	Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hezel AF, Deshpande V and Zhu AX: Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 28:3531–3540. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ortner MA: Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr Opin Gastroenterol. 25:472–476. 2009. View Article : Google Scholar : PubMed/NCBI
7	Gatto M, Bragazzi MC, Semeraro R, et al: Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 42:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
8	Blechacz BR and Gores GJ: Cholangiocarcinoma. Clin Liver Dis. 12:131–150. 2008. View Article : Google Scholar
9	Mihalache F, Hoblinger A, Grunhage F, et al: Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther. 33:389–394. 2011. View Article : Google Scholar : PubMed/NCBI
10	Zhou H, Ortiz-Pallardo ME, Ko Y and Fischer HP: Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer. 88:2668–2676. 2000. View Article : Google Scholar : PubMed/NCBI
11	Hoblinger A and Lammert F: Genetics of biliary tract diseases: new insights into gallstone disease and biliary tract cancers. Curr Opin Gastroenterol. 24:363–371. 2008. View Article : Google Scholar : PubMed/NCBI
12	Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
13	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar
14	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
15	Komarova EA, Krivokrysenko V, Wang K, et al: p53 is a suppressor of inflammatory response in mice. FASEB J. 19:1030–1032. 2005.PubMed/NCBI
16	Gudkov AV and Komarova EA: Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet. 16(Spec No 1): R67–R72. 2007. View Article : Google Scholar : PubMed/NCBI
17	Khan SA, Taylor-Robinson SD, Carmichael PL, Habib N, Lemoine NR and Thomas HC: Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Int J Oncol. 28:1269–1277. 2006.PubMed/NCBI
18	Khan SA, Thomas HC, Toledano MB, Cox IJ and Taylor-Robinson SD: p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 25:704–716. 2005. View Article : Google Scholar : PubMed/NCBI
19	Tannapfel A, Weinans L, Geissler F, et al: Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci. 45:317–324. 2000. View Article : Google Scholar : PubMed/NCBI
20	Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R and DePinho RA: Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66:6622–6627. 2006. View Article : Google Scholar : PubMed/NCBI
21	Whibley C, Pharoah PD and Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer. 9:95–107. 2009. View Article : Google Scholar : PubMed/NCBI
22	Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
23	Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI
24	Khan SA, Davidson BR, Goldin R, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 51(Suppl 6): 1–9. 2002.PubMed/NCBI
25	Hartman M, Loy EY, Ku CS and Chia KS: Molecular epidemiology and its current clinical use in cancer management. Lancet Oncol. 11:383–390. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hattersley AT and McCarthy MI: What makes a good genetic association study? Lancet. 366:1315–1323. 2005. View Article : Google Scholar : PubMed/NCBI
27	Bond GL, Hirshfield KM, Kirchhoff T, et al: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 66:5104–5110. 2006. View Article : Google Scholar : PubMed/NCBI
28	Bond GL and Levine AJ: A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 26:1317–1323. 2007. View Article : Google Scholar
29	Zimmer V, Widmann T, Muller M, et al: Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn’s disease. Digestion. 81:246–251. 2010.PubMed/NCBI
30	Jones JS, Chi X, Gu X, Lynch PM, Amos CI and Frazier ML: p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res. 10:5845–5849. 2004. View Article : Google Scholar : PubMed/NCBI
31	Shen H, Zheng Y, Sturgis EM, Spitz MR and Wei Q: P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 183:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
32	Welzel TM, Graubard BI, El-Serag HB, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 5:1221–1228. 2007. View Article : Google Scholar : PubMed/NCBI
33	Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 19:1092–1100. 1999.PubMed/NCBI
34	Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI